share_log

Jiangsu Huifeng Bio Agriculture (SZSE:002496) Shareholders Are up 20% This Past Week, but Still in the Red Over the Last Five Years

Jiangsu Huifeng Bio Agriculture (SZSE:002496) Shareholders Are up 20% This Past Week, but Still in the Red Over the Last Five Years

江苏辉丰生物农业(SZSE:002496)股东上周上涨了20%,但在过去五年中仍处于亏损状态
Simply Wall St ·  03/19 20:36

Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) shareholders will doubtless be very grateful to see the share price up 52% in the last month. But if you look at the last five years the returns have not been good. After all, the share price is down 28% in that time, significantly under-performing the market.

江苏汇丰生物农业有限公司(深圳证券交易所:002496)股东们无疑将非常感激地看到上个月股价上涨了52%。但是,如果你看看过去的五年,回报并不理想。毕竟,当时股价下跌了28%,表现大大低于市场。

While the stock has risen 20% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.

尽管该股在过去一周上涨了20%,但长期股东仍处于亏损状态,但让我们看看基本面能告诉我们什么。

Because Jiangsu Huifeng Bio Agriculture made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

由于江苏汇丰生物农业在过去十二个月中出现亏损,我们认为至少目前市场可能更加关注收入和收入增长。无利可图的公司的股东通常期望强劲的收入增长。一些公司愿意推迟盈利以更快地增加收入,但在这种情况下,人们确实预计收入会有良好的增长。

Over half a decade Jiangsu Huifeng Bio Agriculture reduced its trailing twelve month revenue by 36% for each year. That puts it in an unattractive cohort, to put it mildly. On the face of it we'd posit the share price fall of 5% compound, over five years is well justified by the fundamental deterioration. We doubt many shareholders are delighted with this share price performance. Risk averse investors probably wouldn't like this one much.

在过去的五年中,江苏汇丰生物农业将其过去十二个月的收入每年减少36%。客气地说,这使它成为一个没有吸引力的群体。从表面上看,我们认为股价在五年内复合下跌了5%,这完全是基本面恶化所证明的。我们怀疑许多股东对这种股价表现感到满意。规避风险的投资者可能不会太喜欢这个。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

公司的收入和收益(随着时间的推移)如下图所示(点击查看确切数字)。

earnings-and-revenue-growth
SZSE:002496 Earnings and Revenue Growth March 20th 2024
SZSE: 002496 2024 年 3 月 20 日收益和收入增长

This free interactive report on Jiangsu Huifeng Bio Agriculture's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想进一步调查该股,这份关于江苏辉丰生物农业资产负债表实力的免费互动报告是一个很好的起点。

A Different Perspective

不同的视角

While the broader market lost about 9.5% in the twelve months, Jiangsu Huifeng Bio Agriculture shareholders did even worse, losing 21%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 5% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Jiangsu Huifeng Bio Agriculture .

尽管整个市场在十二个月中下跌了约9.5%,但江苏汇丰生物农业股东的表现甚至更糟,跌幅为21%。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本发展。遗憾的是,去年的业绩结束了糟糕的表现,股东在五年内每年面临5%的总亏损。总的来说,长期股价疲软可能是一个坏兆头,尽管逆势投资者可能希望研究该股以期出现转机。尽管市场状况可能对股价产生的不同影响值得考虑,但还有其他因素更为重要。为此,你应该注意我们在江苏汇丰生物农业发现的1个警告信号。

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一样,那么你不会想错过这份业内人士正在收购的成长型公司的免费名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发